Results 171 to 180 of about 26,895 (263)

sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes. [PDF]

Mol Ther Nucleic Acids
de Klerk JA, Slieker RC, Beulens JWJ, Peerlings JHD, Mei H, Elders PJM, van Zonneveld AJ, van Raalte DH, Bijkerk R, 't Hart LM.   +9 more
europepmc   +1 more source

Ertugliflozin - SGLT2 inhibitor [PDF]

Interní medicína pro praxi, 2019
openaire   +1 more source

Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial

Journal of Diabetes Investigation, EarlyView.
Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna, Ryoichi Ishibashi, Masaya Koshizaka, Tomoaki Tatsumi, Takayuki Baba, Shuichi Yamamoto, Koutaro Yokote   +6 more
wiley   +1 more source

Efficacy and safety of SGLT2 inhibitor on insulin resistance and hyperglycemia in Werner syndrome-A case report. [PDF]

J Diabetes Investig
Yagi T, Aotani D, Hasegawa C, Shimizu Y, Koyama H, Maezawa Y, Yokote K, Tanaka T.   +7 more
europepmc   +1 more source

Enavogliflozin Improves Non‐invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials

Diabetes, Obesity and Metabolism, EarlyView.
Min Kyoung Jang, Chang Hee Jung, Han Sol Lee, Areum Lee, Su‐Jin Jeoung, Yong‐Ho Lee, Hae Jin Kim, So Hun Kim, Sung Hoon Yu, Suk Chon, In Kyung Jeong   +10 more
wiley   +1 more source

Effect of sodium–glucose cotransporter 2 inhibitors on heart failure readmission in older patients with diabetes: A Japanese claims‐based cohort study

Journal of Diabetes Investigation, EarlyView.
SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura, Hirotaka Masuda, Masayuki Sakunami, Miki Yamashita   +3 more
wiley   +1 more source

Fatal Hypoglycemia in a Nondiabetic Patient With End-Stage Familial Hypertrophic Cardiomyopathy on SGLT2 Inhibitor Therapy. [PDF]

JACC Case Rep
Li Y, Zhong L.
europepmc   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Repurposing SGLT2 inhibitors [PDF]

Nature Reviews Drug Discovery, 2018
openaire   +1 more source